88 related articles for article (PubMed ID: 22789731)
1. [Off-label approval of drug use in a tertiary hospital].
Pérez-Moreno MA; Villalba-Moreno AM; Santos-Ramos B; Marín-Gil R; Varela-Aguilar JM; Torelló-Iserte J; Núñez-Vázquez R; Jiménez-Jiménez J; Bautista-Paloma FJ
Rev Calid Asist; 2013; 28(1):12-8. PubMed ID: 22789731
[TBL] [Abstract][Full Text] [Related]
2. Japanese regulatory system for approval of off-label drug use: evaluation of safety and effectiveness in literature-based applications.
Shimazawa R; Ikeda M
Clin Ther; 2012 Oct; 34(10):2104-16. PubMed ID: 23036337
[TBL] [Abstract][Full Text] [Related]
3. Access to anticancer drugs: many evidence-based treatments are off-label and unfunded by the Pharmaceutical Benefits Scheme.
Mellor JD; Van Koeverden P; Yip SW; Thakerar A; Kirsa SW; Michael M
Intern Med J; 2012 Nov; 42(11):1224-9. PubMed ID: 22372936
[TBL] [Abstract][Full Text] [Related]
4. [Off-label use of psychotropic medications in pediatric wards: a prospective study].
Winterfeld U; Le Heuzey MF; Acquaviva E; Mouren MC; Brion F; Bourdon O
Arch Pediatr; 2009 Sep; 16(9):1252-60. PubMed ID: 19640689
[TBL] [Abstract][Full Text] [Related]
5. [Off-label use of oncology drugs: national survey results].
González-Haba Peña E; Agustín Ferrández MJ; Mangues Bafalluy I; Alfredo López N; Fraga Fuentes MD; Marín Gil R; Martínez Bautista MJ; Clopés Estela A
Farm Hosp; 2015 Sep; 39(5):275-87. PubMed ID: 26546940
[TBL] [Abstract][Full Text] [Related]
6. Innovating by developing new uses of already-approved drugs: trends in the marketing approval of supplemental indications.
DiMasi JA
Clin Ther; 2013 Jun; 35(6):808-18. PubMed ID: 23726388
[TBL] [Abstract][Full Text] [Related]
7. Drug, patient, and physician characteristics associated with off-label prescribing in primary care.
Eguale T; Buckeridge DL; Winslade NE; Benedetti A; Hanley JA; Tamblyn R
Arch Intern Med; 2012 May; 172(10):781-8. PubMed ID: 22507695
[TBL] [Abstract][Full Text] [Related]
8. Drug approval processes in Australian Paediatric Hospitals.
Sinha YK; Craig JC; Barclay P; Taitz J; South M; Coulthard K; Pearson C; Erickson S; Brien JE
Arch Dis Child; 2010 Sep; 95(9):739-44. PubMed ID: 20584852
[TBL] [Abstract][Full Text] [Related]
9. Effect of off-label use of oncology drugs on pharmaceutical costs: the rituximab experience.
Kocs D; Fendrick AM
Am J Manag Care; 2003 May; 9(5):393-400; quiz 401-2. PubMed ID: 12744301
[TBL] [Abstract][Full Text] [Related]
10. Off-label antidepressant use in children and adolescents compared with young adults: extent and level of evidence.
Czaja AS; Valuck R
Pharmacoepidemiol Drug Saf; 2012 Sep; 21(9):997-1004. PubMed ID: 22760843
[TBL] [Abstract][Full Text] [Related]
11. Drug utilization study in pediatric prescriptions of a university hospital in southern Brazil: off-label, unlicensed and high-alert medications.
Dos Santos L; Heineck I
Farm Hosp; 2012; 36(4):180-6. PubMed ID: 22030161
[TBL] [Abstract][Full Text] [Related]
12. U.S. physician knowledge of the FDA-approved indications and evidence base for commonly prescribed drugs: results of a national survey.
Chen DT; Wynia MK; Moloney RM; Alexander GC
Pharmacoepidemiol Drug Saf; 2009 Nov; 18(11):1094-100. PubMed ID: 19697444
[TBL] [Abstract][Full Text] [Related]
13. Assessment of new drugs in a tertiary hospital using a standardized tool.
González-Bueno J; Chamorro-de-Vega E; Alfaro-Lara ER; Galván-Banqueri M; Santos-Ramos B
Farm Hosp; 2013; 37(5):388-93. PubMed ID: 24128101
[TBL] [Abstract][Full Text] [Related]
14. Food and Drug Administration approval for medications used in the pediatric intensive care unit: a continuing conundrum.
Yang CP; Veltri MA; Anton B; Yaster M; Berkowitz ID
Pediatr Crit Care Med; 2011 Sep; 12(5):e195-9. PubMed ID: 21057369
[TBL] [Abstract][Full Text] [Related]
15. Changes in anticonvulsant prescribing for Australian children: implications for Quality Use of Medicines.
Cohen SA; Lawson JA; Graudins LV; Pearson SA; Gazarian M
J Paediatr Child Health; 2012 Jun; 48(6):490-5. PubMed ID: 22050665
[TBL] [Abstract][Full Text] [Related]
16. Descriptive review and analysis of immunoglobulin utilization management from 2,548 prior authorization requests.
Tonkovic B; Rutishauser LK
J Manag Care Spec Pharm; 2014 Apr; 20(4):357-67. PubMed ID: 24684640
[TBL] [Abstract][Full Text] [Related]
17. Use of wet nebulized inhaled respiratory medications under criteria-based reimbursement guidelines in a publicly funded Seniors' Pharmacare Program in Nova Scotia, Canada.
Bowles SK; Sketris I; Kephart G;
Am J Geriatr Pharmacother; 2007 Jun; 5(2):120-8. PubMed ID: 17719514
[TBL] [Abstract][Full Text] [Related]
18. In-label and off-label use of respiratory drugs in the Italian paediatric population.
Baiardi P; Ceci A; Felisi M; Cantarutti L; Girotto S; Sturkenboom M; Baraldi E
Acta Paediatr; 2010 Apr; 99(4):544-9. PubMed ID: 20105140
[TBL] [Abstract][Full Text] [Related]
19. Physician-pharmacist agreement about off-label use of medications in private clinical settings in Baghdad, Iraq.
Hussain SA; Abbas AN; Alhadad HA; Al-Jumaili AA; Abdulrahman ZS
Pharm Pract (Granada); 2017; 15(3):979. PubMed ID: 28943980
[TBL] [Abstract][Full Text] [Related]
20. Off-label use of medicines in paediatric inpatients at an Australian teaching hospital.
Ballard CD; Peterson GM; Thompson AJ; Beggs SA
J Paediatr Child Health; 2013 Jan; 49(1):38-42. PubMed ID: 23279160
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
